Hannon J P, Petrucci C, Fehlmann D, Viollet C, Epelbaum J, Hoyer D
Nervous System Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.
Neuropharmacology. 2002 Mar;42(3):396-413. doi: 10.1016/s0028-3908(01)00186-1.
The peptide hormone/neurotransmitter somatostatin (somatotropin release inhibiting factor; SRIF) and its receptors (sst(1)-sst(5)) appear to regulate many physiological functions in the CNS. Semi-quantitative analysis of the densities of mRNA expression for sst(1-5) receptors and SRIF receptor binding sites were established in sst(2) receptor knock-out (KO) mice. Patterns of sst(1-5) receptor mRNA expression were largely conserved for sst(1,3,4) and sst(5) selective oligonucleotide probes; whereas sst(2) signals were completely absent in KO mouse brain. Autoradiographic analysis demonstrated [(125)I]LTT SRIF(28), [(125)I]CGP 23996 (two radioligands known to label all five recombinant SRIF receptors) and [(125)I]Tyr(3)-octreotide (sst(2) and sst(5) receptor selective) binding in wild type (WT) mouse brain sections; yet no specific binding of [(125)I]Tyr(3)-octreotide in KO mice. In contrast, [(125)I]LTT SRIF(28) and [(125)I]CGP 23996 binding was still present in a number of brain areas in KO mice, although to a lesser degree than in those regions where [(125)I]Tyr(3)-octreotide binding was found, in WT animals. The present data suggest first, that both sst(2) receptor protein and mRNA were completely absent in the brain of these KO animals. Second, there was little evidence of compensatory regulation, at the mRNA level, of the other SRIF receptors as a consequence of the sst(2) KO. Third, the absence of any [(125)I]Tyr(3)-octreotide binding, in KO mice, suggests that this particular ligand is selective for the sst(2) receptor subtype (under the conditions utilised); or that sst(5) receptors are only marginally expressed in brain. Fourth, there were regions where the binding of [(125)I]LTT SRIF(28) and [(125)I]CGP 23996 were moderately affected by the sst(2) KO, suggesting that additional SRIF receptors may well contribute to the binding of the aforementioned radioligands. Finally, since the relative distribution of these two ligands were not entirely superimposable, it suggests that their respective selectivity profiles towards the different SRIF receptor subtypes in situ are not identical.
肽类激素/神经递质生长抑素(促生长激素释放抑制因子;SRIF)及其受体(sst(1)-sst(5))似乎在中枢神经系统中调节许多生理功能。在sst(2)受体基因敲除(KO)小鼠中建立了sst(1-5)受体mRNA表达密度和SRIF受体结合位点的半定量分析。对于sst(1、3、4)和sst(5)选择性寡核苷酸探针,sst(1-5)受体mRNA表达模式在很大程度上是保守的;而在KO小鼠脑中完全没有sst(2)信号。放射自显影分析显示,[(125)I]LTT SRIF(28)、[(125)I]CGP 23996(已知可标记所有五种重组SRIF受体的两种放射性配体)和[(125)I]Tyr(3)-奥曲肽(sst(2)和sst(5)受体选择性)在野生型(WT)小鼠脑切片中有结合;然而在KO小鼠中没有[(125)I]Tyr(3)-奥曲肽的特异性结合。相反,[(125)I]LTT SRIF(28)和[(125)I]CGP 23996结合在KO小鼠的一些脑区中仍然存在,尽管程度低于在WT动物中发现[(125)I]Tyr(3)-奥曲肽结合的区域。目前的数据表明,首先,这些KO动物脑中完全不存在sst(2)受体蛋白和mRNA。其次,几乎没有证据表明由于sst(2)基因敲除,其他SRIF受体在mRNA水平上有代偿性调节。第三,KO小鼠中没有任何[(125)I]Tyr(3)-奥曲肽结合,表明这种特定配体对sst(2)受体亚型具有选择性(在所使用的条件下);或者sst(5)受体在脑中仅少量表达。第四,存在一些区域,其中[(125)I]LTT SRIF(28)和[(125)I]CGP 23996的结合受到sst(2)基因敲除的中度影响,这表明其他SRIF受体很可能有助于上述放射性配体的结合。最后,由于这两种配体的相对分布并不完全重叠,这表明它们在原位对不同SRIF受体亚型的各自选择性谱并不相同。